This is the first human interventional study in patients with Cowden syndrome that is driven by inactivation of germline PTEN gene.
LESSONS LEARNED
• This is the first human interventional study in patients with Cowden syndrome that is driven by inactivation of germline PTEN gene. • Single-agent sirolimus, a mTOR inhibitor, suppressed mTOR signaling in surrogate human tissues without significant toxicity.
ABSTRACT
Background. Cowden syndrome is characterized by inactivating germline PTEN mutations, which can lead to activation of the PI3K-Akt-mTOR pathway. Methods. Adult subjects with germline PTEN mutation who met international diagnostic criteria for Cowden syndrome and who had Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and adequate organ function were enrolled. Subjects were treated with a 56-day course of daily oral sirolimus. In addition to symptom assessment and physical examination, dermatologic, endoscopic, neurologic (cerebellar), and radiographic assessments were conducted. Inhibition of the mTOR pathway in benign skin and gastrointestinal (GI) lesion was assessed by immunohistochemistry. Results. A total of 18 patients and 16 families were enrolled. PTEN mutations were located at exons 1-8. Regression of skin and GI lesions was observed by dermoscopy or endoscopy. Neurological evaluation showed improvement in cerebellar function score at 1 month. Immunohistochemistry (IHC) analysis in skin and GI benign lesions showed a decrease in the ratio of phosphorylated (p)S6 to total S6 in response to sirolimus. Ratios of pS6K to total S6 at days 14 and 56 were significantly lower than at baseline (p = .0026, p = .00391, respectively). A 56-day course of sirolimus was well tolerated. Conclusion. A 56-day course of sirolimus was well tolerated in subjects with Cowden syndrome and was associated with some evidence of improvement in symptoms, skin and GI lesions, cerebellar function, and decreased mTOR signaling. The Oncologist 2019;24:1510-e1265
DISCUSSION
Cowden syndrome is a rare, hereditary cancer syndrome that is characterized by germline PTEN mutation and development of malignant and benign tumors in various organs. There are several additional syndromes that are also driven by inactivated PTEN gene. There is no recommended systemic agent that can prevent cancer development in these syndromes. This is the first human study to investigate if sirolimus, a mTOR inhibitor that is clinically available as an immunosuppressive agent after organ transplantation, can modulate mTOR signaling in surrogate tissues in subjects with Cowden syndrome. Other endpoints included change in subjective symptoms, physical examination, dermatologic, endoscopic, neurologic (cerebellar), and radiographic assessments.
A total of 18 patients (16 families) with germline PTEN mutation were enrolled.
Overall, a 56-day course of sirolimus was well tolerated. Common toxicities (all grades >30%) are abnormalities in liver enzymes (39%), electrolytes (33%), and anemia (33%). With the exception of two individuals who developed grade 3 toxicities (hypophosphatemia and lymphopenia), all the remaining toxicities were grade 1 or 2, and none required dose modification. There was no pneumonitis in any of the participants.
Activity of sirolimus was evaluated by subjective and objective assessments. A majority (67%) of patients reported improvement in baseline symptoms. Dermatologic and endoscopic examinations showed improvement in skin (14/18, 77.8%) and GI polyps (2/14, 14.3%), respectively. Cerebellar function as assessed by the modified Scale for the Assessment and Rating of Ataxia (SARA) method showed a significant improvement in a total SARA score at one month (n = 9, p = .034, data not shown). Imaging studies for patients with measurable or positron emission tomography avid tumor were also assessed. Of the five patients with radiographically measurable disease, all showed stable disease by repeat computed tomography (CT) and magnetic resonance imaging (MRI) at day 56.
Biomarker analysis using biopsied skin or GI tissue was conducted. The ratio of pS6 to total S6 significantly decreased in response to sirolimus treatment at day 15 and day 56 ( Fig. 1 ; p = .0026 and p = .00391, respectively). A median sirolimus trough level at day 28 was 6.7 ng/mL. There was no significant correlation between the trough level and grade 3 toxicities.
Given the tolerability, clinical availability, and target inhibition in surrogate tissue in this study, the use of sirolimus for the prevention of malignancy in patients with Cowden syndrome deserves further investigation. Duration and optimal dosing and scheduling of sirolimus for cancer prevention in this high-risk patient population need to be further defined.
TRIAL INFORMATION

Disease
Cowden syndrome as defined by International Cowden Consortium operational criteria, version 2000.
Stage of Disease/Treatment Prevention
Prior Therapy
No designated number of regimens Pharmacokinetics and correlative studies: Serum trough levels of sirolimus were measured at baseline, day 15, and day 56 of the study. Immunohistochemistry of the biopsied materials were conducted for total S6, pS6, and pS6K and scored by traditional semiquantitative method (i.e., 0, 1+, 2+, 3+).
Statistics: This pilot study intended to enroll a total of up to 15 subjects, and it was considered desirable if at least 10 of these patients had six paired lesions amenable to biopsy for IHC in order to create a measure with reasonable statistical precision. The protocol was later amended to allow up to 20 patients. However, this study with a small sample size was not expected to provide any definitive conclusion but rather to generate hypotheses. The Wilcoxon signed-rank test was used when comparing two matched samples. A p value <.05 was considered as statistically significant.
Investigator's Analysis
Active and should be pursued further 
PHARMACOKINETICS/PHARMACODYNAMICS
Sirolimus trough level: median (range): 6.7 ng/mL (3.0-3.9)
ASSESSMENT, ANALYSIS, AND DISCUSSION
Completion Study terminated before completion
Terminated Reason Did not fully accrue. Original PI left institution
Investigator's Assessment Active and should be pursued further A number of oncogenic signaling pathways have been described as drivers of cell growth and survival in human cancers. The PI3K-Akt-mTOR pathway is activated in human malignancies, and several familial cancer syndromes with underlying genetic alterations are linked with this pathway. For instance, germline mutations in PTEN, TSC2, and STK11, which negatively regulate PI3K-Akt signaling, are linked with PTEN hamartoma tumor syndrome (PHTS), tuberous sclerosis syndrome, and Peutz-Jeghers syndrome, respectively [1] .
PHTS encompasses multiple clinical syndromes with germline PTEN mutation. These include Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndrome, all of which are characterized by germline PTEN mutation [1, 2] .
Cowden syndrome is an autosomal-dominant, cancer susceptibility disorder in adulthood that is driven by germline mutation in a tumor suppressor, PTEN. PTEN is a dual phosphatase that dephosphorylates both protein and phospholipid substrates. Loss of PTEN function leads to upregulation of the PI3K-Akt-mTOR pathway. Clinical features characteristic of Cowden syndrome include benign skin lesions, macrocephaly, intestinal polyposis, and malignancies in thyroid, breast, endometrium, intestine, and kidney [3] . Manifestations in skin range from acral keratosis to trichilemmomas to mucosal papillomatosis, whereas intestinal lesions include polyposis and malignancies.
In order to assist clinicians in the management of Cowden syndrome, the International Cowden Consortium established the first operational diagnostic criteria for PHTS in 1995, which was later revised in 2000 [4] . It was based on estimated risks of cancer and genotype-phenotype correlation in a total of 12 families with PHTS. Based on a study with over 3,000 cases, a new scoring system to assist clinicians in considering germline PTEN mutation tests was proposed in 2011 as well [5] . Most recently, a prospective study of 3,399 cases meeting the relaxed international diagnostic criteria with a subset of 368 cases with deleterious germline PTEN mutation was reported [3] . Increased lifetime risk of cancer was found for carcinomas of breast, thyroid, endometrium, colorectum, kidney, and melanoma. This study recommended detailed cancer screening procedures for individuals with germline PTEN mutation.
Despite known cancer susceptibility and recommended cancer screening procedures, there has been no interventional or prevention study in humans with Cowden syndrome. Activation of Akt-mTOR signaling as a result of loss of PTEN can be theoretically counteracted by mTOR inhibitors in humans. Individuals with activated mTOR signaling likely benefit from mTOR inhibitors with tolerable toxicities. Here we present a pilot study intended to determine tolerability of sirolimus (rapamycin) and its modulation of mTOR signaling in human subjects with Cowden syndrome. This pilot study in patients with Cowden syndrome aimed to assess feasibility of treatment with sirolimus and modulation of mTOR signaling in accessible benign lesions (i.e., skin and gastrointestinal polyps). Administration of oral sirolimus 2 mg daily was tolerable and required no dose modification. Although pulmonary toxicity is anticipated for mTOR inhibitors, we observed no pneumonitis in this study. Although this study was exploratory, improvements in subjective and objective assessments such as cerebellar function seemed promising. mTOR signaling as determined by pS6-total S6 ratio was suppressed in response to sirolimus treatment.
Several human studies have also investigated if mTOR inhibitors can benefit patients with other nonmalignant conditions with activated Akt-mTOR signaling. For instance, McCormack et al. treated 89 patients with lymphangioleiomyomatosis (LAM) [6] . This condition is a progressive, cystic lung disease in young women, associated with activated mTOR as a result of defective tuberous sclerosis complex (TSC) gene. Loss of the TSC gene results in constitutive activation of mTOR signaling, suggesting mTOR is a therapeutic target in LAM. This study demonstrated that a 12-month administration of sirolimus (2 mg daily) is tolerable and improved pulmonary function compared with placebo. Benign tumors regulated by mTOR signaling can also benefit from targeting mTOR. Everolimus, a rapamycin analogue, has activity in patients with defective TSC and subependymal giant cell astrocytoma [7] . These clinical findings suggest that a mTORdriven benign condition with inactivation of various negative regulators such as PTEN may respond to mTOR targeted therapy.
This study is limited by its single arm, small sample size, and short exposure to the study drug. We acknowledge that confirmatory studies are required to define effectiveness in Cowden syndrome. Long-term administration of 2-mg daily sirolimus is reportedly tolerable in patients with LAM. We believe the current study provides meaningful information for studies planned in the future.
